Last updated on July 2019

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers


Brief description of study

The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma.

The primary objectives in the dose expansion phase are to assess preliminary anti-tumor activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as measured by objective response rate (ORR).

Clinical Study Identifier: NCT03005782

Find a site near you

Start Over

The Angeles Clinic

Los Angeles, CA United States
  Connect »

Henry Ford Health Hospital

Detroit, MI United States
  Connect »

Stephenson Cancer Center

Oklahoma City, OK United States
  Connect »

Rhode Island Hospital

Providence, RI United States
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Guy's Hospital

London, United Kingdom
  Connect »